432 related articles for article (PubMed ID: 36755812)
41. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.
Garg AD; Agostinis P
Immunol Rev; 2017 Nov; 280(1):126-148. PubMed ID: 29027218
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in targeting cancer stem cells using oncolytic viruses.
Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
[TBL] [Abstract][Full Text] [Related]
43. Targeting immunogenic cell death in cancer.
Ahmed A; Tait SWG
Mol Oncol; 2020 Dec; 14(12):2994-3006. PubMed ID: 33179413
[TBL] [Abstract][Full Text] [Related]
44. Design and application of oncolytic viruses for cancer immunotherapy.
Ylösmäki E; Cerullo V
Curr Opin Biotechnol; 2020 Oct; 65():25-36. PubMed ID: 31874424
[TBL] [Abstract][Full Text] [Related]
45. Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy.
Yang S; Sun IC; Hwang HS; Shim MK; Yoon HY; Kim K
J Mater Chem B; 2021 May; 9(19):3983-4001. PubMed ID: 33909000
[TBL] [Abstract][Full Text] [Related]
46. Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers.
Chiaravalli M; Spring A; Agostini A; Piro G; Carbone C; Tortora G
Cells; 2022 Sep; 11(19):. PubMed ID: 36230995
[TBL] [Abstract][Full Text] [Related]
47. Oncolytic Viruses and Cancer Immunotherapy.
Malhotra J; Kim ES
Curr Oncol Rep; 2023 Jan; 25(1):19-28. PubMed ID: 36441447
[TBL] [Abstract][Full Text] [Related]
48. The two-faces of NK cells in oncolytic virotherapy.
Marotel M; Hasim MS; Hagerman A; Ardolino M
Cytokine Growth Factor Rev; 2020 Dec; 56():59-68. PubMed ID: 32586674
[TBL] [Abstract][Full Text] [Related]
49. SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
Gujar S; Bell J; Diallo JS
Cell; 2019 Feb; 176(5):1240-1240.e1. PubMed ID: 30794777
[TBL] [Abstract][Full Text] [Related]
50. Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines.
Holay N; Kim Y; Lee P; Gujar S
Front Immunol; 2017; 8():800. PubMed ID: 28751892
[TBL] [Abstract][Full Text] [Related]
51. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.
Marelli G; Howells A; Lemoine NR; Wang Y
Front Immunol; 2018; 9():866. PubMed ID: 29755464
[TBL] [Abstract][Full Text] [Related]
52. Armed oncolytic viruses: A kick-start for anti-tumor immunity.
de Graaf JF; de Vor L; Fouchier RAM; van den Hoogen BG
Cytokine Growth Factor Rev; 2018 Jun; 41():28-39. PubMed ID: 29576283
[TBL] [Abstract][Full Text] [Related]
53. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
[TBL] [Abstract][Full Text] [Related]
54. Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy.
Wang J; Ma J; Xie F; Miao F; Lv L; Huang Y; Zhang X; Yu J; Tai Z; Zhu Q; Bao L
Front Immunol; 2024; 15():1389173. PubMed ID: 38745666
[TBL] [Abstract][Full Text] [Related]
55. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.
Oh CM; Chon HJ; Kim C
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33086754
[TBL] [Abstract][Full Text] [Related]
56. Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy.
Sansone C; Bruno A; Piscitelli C; Baci D; Fontana A; Brunet C; Noonan DM; Albini A
Cells; 2021 Jan; 10(2):. PubMed ID: 33504012
[TBL] [Abstract][Full Text] [Related]
57. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
58. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
59. Potentiating prostate cancer immunotherapy with oncolytic viruses.
Lee P; Gujar S
Nat Rev Urol; 2018 Apr; 15(4):235-250. PubMed ID: 29434366
[TBL] [Abstract][Full Text] [Related]
60. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
